Analysts Offer Predictions for NRIX FY2026 Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Analysts at HC Wainwright issued their FY2026 earnings per share estimates for Nurix Therapeutics in a research report issued to clients and investors on Tuesday, July 1st. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($3.33) per share for the year. HC Wainwright currently has a "Buy" rating and a $36.00 target price on the stock. The consensus estimate for Nurix Therapeutics' current full-year earnings is ($2.99) per share.

A number of other research analysts have also recently commented on NRIX. Wells Fargo & Company cut their price target on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday, April 9th. Leerink Partnrs upgraded Nurix Therapeutics to a "hold" rating in a research report on Monday, March 17th. Leerink Partners assumed coverage on Nurix Therapeutics in a research report on Monday, March 17th. They issued a "market perform" rating and a $16.00 price target on the stock. Wall Street Zen upgraded Nurix Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st. Finally, Stifel Nicolaus cut their price objective on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $30.18.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock traded up $0.29 during trading on Wednesday, hitting $12.73. 279,635 shares of the company's stock traded hands, compared to its average volume of 835,600. The company has a market cap of $970.54 million, a PE ratio of -4.55 and a beta of 2.15. The firm's fifty day moving average price is $11.10 and its 200 day moving average price is $14.16. Nurix Therapeutics has a twelve month low of $8.18 and a twelve month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The firm had revenue of $18.45 million for the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative net margin of 369.40% and a negative return on equity of 47.49%. During the same quarter in the previous year, the company earned ($0.76) earnings per share.

Insider Buying and Selling

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of the company's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the transaction, the insider owned 61,516 shares of the company's stock, valued at approximately $707,434. This represents a 5.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 6,198 shares of Nurix Therapeutics stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the sale, the chief financial officer directly owned 33,724 shares of the company's stock, valued at $382,092.92. This trade represents a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,013 shares of company stock worth $137,096 over the last quarter. 7.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Nurix Therapeutics

Large investors have recently made changes to their positions in the company. Rhumbline Advisers raised its holdings in Nurix Therapeutics by 13.5% during the 4th quarter. Rhumbline Advisers now owns 103,233 shares of the company's stock worth $1,945,000 after purchasing an additional 12,315 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Nurix Therapeutics by 8.9% during the 4th quarter. Bank of New York Mellon Corp now owns 190,905 shares of the company's stock worth $3,597,000 after buying an additional 15,639 shares during the period. Proficio Capital Partners LLC bought a new stake in shares of Nurix Therapeutics during the fourth quarter worth approximately $376,000. US Bancorp DE lifted its holdings in Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after buying an additional 842 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Nurix Therapeutics by 11.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 572,834 shares of the company's stock valued at $10,792,000 after buying an additional 61,114 shares during the period.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.